Clinical trial design of serious gaming in mild cognitive impairment by Cristina Muscio et al.
OPINION
published: 11 March 2015
doi: 10.3389/fnagi.2015.00026
Frontiers in Aging Neuroscience | www.frontiersin.org 1 March 2015 | Volume 7 | Article 26
Edited by:
Philippe Robert,
University of Nice Sophia Antipolis,
France
Reviewed by:
Alexandra König,
EA CoBTek CHU de Nice - Université
de Nice Sophia Antipolis, France
Julian Alvarez,
Lille1 University, France
Francois Bremond,
Inria, France
*Correspondence:
Cristina Muscio,
cristina.muscio@gmail.com
Received: 18 January 2015
Accepted: 23 February 2015
Published: 11 March 2015
Citation:
Muscio C, Tiraboschi P, Guerra UP,
Defanti CA and Frisoni GB (2015)
Clinical trial design of serious gaming
in mild cognitive impairment.
Front. Aging Neurosci. 7:26.
doi: 10.3389/fnagi.2015.00026
Clinical trial design of serious
gaming in mild cognitive impairment
Cristina Muscio 1, 2*, Pietro Tiraboschi 3, Ugo P. Guerra 4, Carlo A. Defanti 1 and
Giovanni B. Frisoni 5, 6
1 Fondazione Europea Ricerca Biomedica, Centro Eccellenza Alzheimer, Ospedale Briolini, Bergamo, Italy, 2Department of
Molecular and Translational Medicine, University of Brescia, Brescia, Italy, 3Division of Neurology V/Neuropathology,
Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy, 4 Fondazione Poliambulanza, Nuclear Medicine
Department, Brescia, Italy, 5 Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS Centro San Giovanni di
Dio-Fatebenefratelli, Brescia, Italy, 6Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals
and University of Geneva, Geneva, Switzerland
Keywords: serious games, Alzheimer’s disease, mild cognitive impairment, biomarker enrichment strategy,
outcome measures, clinical trials
Introduction
The “Global Impact of Dementia: 2013–2050” (Alzheimer’s Disease International, 2013), released
ahead of the December 2013 G8 Dementia Summit in London, estimated that 44.35 million peo-
ple in the world were living with dementia in 2013. This number was predicted to increase to 75.6
million in 2030, and 135.5 million in 2050. This dramatic increase will have profound implications
for social and economic costs (Alzheimer’s Disease International, 2010). Since the most common
dementia subtype (50–75%) is Alzheimer’s disease (AD), its early detection and clinical effectiveness
of its prevention and treatment represent a major public health concern and have been identified as
a research priority (Alzheimer’s Disease International, 2009; Ballard et al., 2011; Foster et al., 2014).
Recently, there has been a growing interest in employing Information and Communication
Technologies (ICT) to evaluate patient’s cognitive and functional impairment for early detection of
AD (Wan Shamsuddin et al., 2011; Tarnanas et al., 2014). Beyond being important for assessment,
ICT can also play a key role in the patient’s treatment, stimulation, and rehabilitation (Robert et al.,
2014). This is the idea underlying the current use of Serious Games (SGs), which are a broader reap-
plication of videogames resources integrating gaming and serious purposes. Lately, a few studies
have started to investigate the efficacy of SGs used as an ICT intervention, which target cognitive
decline, in people with AD and mild cognitive impairment (MCI). Until now, however, rigorous
studies are still lacking. To overcome the current methodological issues and to evaluate the efficacy
of SGs in secondary prevention (that currently is being pursued and is considered one of the poten-
tially attainable goals of treatment, Foster et al., 2014), the purpose of the present opinion paper
is to highlight the importance of defining harmonized SGs parameters, and to propose the imple-
mentation of biomarkers as enrichment strategy and outcomemeasures in SGs trial design.We will
now review the history and state-of-art types and use of SGs, before describing in more detail our
proposal.
History of Serious Games: Origin, Typologies, Target
SGs are games designed for a primary purpose other than entertainment, enjoyment or fun
(Michael and Chen, 2005). The historical origin of this oxymoron dates back to Neo-Platonists,
who referred the term “serio ludere” to light-hearted approach in literature dealing with serious
matters (Manning, 2004). The first use of SG oxymoron close to its current use seems to be
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in book written (Abt’s, 1970), even though with a more extensive
meaning. In fact, a SG could indeed be a computer game, a
game, a role-playing game or even an outdoor game (Alvarez and
Djaouti, 2012). The SG term in a digital context was firstly used
in 2002, with the start of the Serious Game Initiative led by David
Rejeski and Ben Sawyer in the US (De Gloria et al., 2014).
To date, SGs have been applied in many sectors, including
education, training, defense, health, communications, market-
ing, politics, and the list is continually expanding (Alvarez and
Djaouti, 2012). Since SGs addresses a set of markets, they are con-
stituted by a wide variety of different types. Considering the dual
nature of SGs, a system that classifies SGs according to both the
“serious” and the “game” dimensions was proposed by Djaouti
et al. (2011)1. This model has classified 3080 SGs so far.
Examples of SGs include (see Alvarez and Djaouti, 2012, for
a review): (i) military games, commonly dedicated to tactical
and strategic training as well as recruitment for the army; (ii)
edugames for educational and training purposes, also usable in a
school context; (iii) advergames, where the gameplay is centered
around a commercial message; (iv) newsgames that are based on
current events or certain journalistic issues; (v) SGs dedicated
to health sector aimed to improve player’s cognitive or physical
abilities; etc.
SGs do not target exclusively young gamers. A consider-
able proportion (20–29%) of regular digital gamers are indeed
older than 50 years (ESA, 2011; BIU, 2014). In this respect,
it is worth noting the increase by 32% in the number of US
females gamers aged 50 and older from 2012 to 2013 (ESA, 2014).
Because the number of elderly people who play video games in
the past decades has steadily increased and is predicted to grow
further (Robert et al., 2014), even small beneficial effects may
have significant public health implications (Alzheimer’s Disease
International, 2014).
The State-of-Art Use of Cognitive Serious
Games with Healthy Older Adults and Ad
Patients
The cognitive effect of SGs played by older adults has not yet been
studied thoroughly (Weybright et al., 2010; Alzheimer’s Disease
International, 2014). In the context of research focused on suc-
cessful cognitive aging and on the possibility to modify the cogni-
tive decline normally associated with healthy aging (Zinke et al.,
2014), anyway, SGs have been demonstrated to be a motivating
tool with some beneficial effects in improving cognitive functions
in healthy older adults (Nouchi et al., 2012; Anguera et al., 2013).
In the study reported by Anguera et al. (2013), indeed, it’s worth
mentioning that: (i) SG improved both trained and untrained
cognitive abilities, which is commonly referred to as a transfer
effect, that is the effect due to a training not only on skills or
performance that are trained, but also on skills or performance
that are not trained (Nouchi et al., 2012); (ii) untrained abilities
that improved were sustained attention and working memory,
which are known to be involved in everyday functioning; and
1http://serious.gameclassification.com
(iii) performance gains remained stable 6 months after train-
ing without booster sessions. This transfer effect of SG on the
improvement of executive functions and processing speeds in
the elderly has been also demonstrated with a short-term train-
ing (Nouchi et al., 2012), suggesting that a possible transfer effect
from laboratory-based tasks to real world ones may be expected.
Neurophysiological findings support training-induced neuro-
plasticity as the mechanistic basis of these SG effects (Anguera
et al., 2013).
However, whether AD patients or population at high risk for
developing AD (i.e., MCI) may benefit from SGs is unknown
(Robert et al., 2014).
Recently, some studies have started to employ SGs with peo-
ple with AD and MCI as a cutting-edge cognition-focused inter-
vention (Table 1). Cognition-focused interventions fall under
the broader umbrella of non-pharmacological interventions, and
can be defined as interventions that directly or indirectly tar-
get cognitive functioning as opposed to interventions that focus
primarily on behavioral, emotional or physical functions (Bahar-
Fuchs et al., 2013). These interventions are typically designed to
promote intellectual stimulation and minimize cognitive impair-
ment (Weybright et al., 2010). Progressive decline of cognitive
functions is indeed a clinical feature of AD and has been found
to be associated with impairment in activities of daily living
(Tomaszewski Farias et al., 2009). Thus, intervention aimed at
prevention and rehabilitation of such decline may promote a
longer independent life at home and decrease the burden of
dementia on patients and families.
Despite the promising results and the increasing interest in
applying cognitive SGs to AD/MCI patients, rigorous feasibil-
ity and efficacy studies are still lacking, partly reflecting the only
recent interest in employing SGs in cognitively impaired patients
(Robert et al., 2014). The main methodological issues are: limi-
tation of randomized controlled studies and lack of harmonized
procedures (i.e., absence of standardized SG parameters such as
when, where and with whom SGs have to be played), as well as
small sample size and questionable choice of patient selection and
outcome measures. However, these issues are common in studies
addressing cognition-focused interventions (Woods et al., 2012;
Bahar-Fuchs et al., 2013).
Future Perspectives
Definition of Harmonized SGS Parameters
To overcome the current lack of harmonized procedures, one
important aspect to be taken into account in the SG trial design
includes the definition of parameters such as when, where and
with whom SGs are more adapted to be played by AD/MCI
patients.
According to the recommendations reported in (Robert et al.,
2014), SGs for MCI patients’ stimulation could be considered
adapted to be used both everyday and once a week; at home,
in day centers and in the nursing homes; with a therapist, a
professional caregiver and a family caregiver.
In our opinion, SG trials should take into account these
methodological recommendations, and assess SG feasibility and
efficacy due to when, where, with whom SG is played by patients.
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As far as “with whom” is concerned, we think that it could also be
interesting to study SGs played by multiple players physically co-
present or by online patients connected from remote locations.
One of SG strengths is indeed its possible role in promoting social
interactions among patients with cognitive impairment (Robert
et al., 2014).
Biomarkers as Enrichment Strategy and
Outcome Measures
It is generally estimated that up to one third of patients enrolled
in AD trials do not have AD (Delrieu et al., 2014), lead-
ing to dilution of observable treatment effects (Aisen, 2011).
However, AD pathology can be identified in living subjects
through pathophysiological markers indicative of abnormal
amyloid deposition that, in addition to a specific cognitive
profile, moves a patient from a status of MCI of unde-
termined etiology to that of prodromal AD (Dubois et al.,
2014). CSF Aβ1-42 and/or PET-amyloid imaging, as well as
hippocampal atrophy on MRI, have indeed been qualified as
enrichment biomarkers to enroll predemented AD subjects in
regulatory clinical trials (see EMA/CHMP/SAWP/893622/2011
and EMA/CHMP/SAWP/809208/2011 qualification opinions).
Inclusion of biomarkers into clinical trials for treatment of
early AD has until now been recommended for pharmacolog-
ical studies alone. However, both pharmacological and non-
pharmacological studies can share the same issues that may
have contributed to their failures (Doody et al., 2014; Salloway
et al., 2014), including for example misdiagnosis of patients and
insensitivity of outcome measures.
To overcome the above-mentioned limitations of cognition-
focused interventions pertaining to patient selection and
outcome measures, and to evaluate the efficacy of SG in sec-
ondary prevention, we propose to implement in the SG trial
design: (i) a biomarker enrichment strategy to enroll MCI due
to AD, and (ii) the use of biomarkers as outcome measures in
combination with clinical ones.
A biomarker enrichment strategy would be expected to sup-
port screening out non-AD cases and screening in AD ones,
reducing the diagnostic inaccuracy at enrollment and, thus, min-
imizing the masking of treatment effects that occurs when mis-
diagnosed patients are recruited (Morris and Selkoe, 2011). Once
identified MCI due to AD using enrichment biomarkers, it could
also be relevant to randomize these patients after stratifying
them into different groups based on positivity on one or more
biomarkers, in order to evaluate a possible differential effect of
SG on MCI subjects presumably at different pre-dementia stages
of the AD process. MCI patients with brain amyloidosis and neu-
rodegeneration are indeed at higher risk of dementia in the fol-
lowing years. According to the current pathophysiologicmodel of
AD (Jack et al., 2010), they might be at a more advanced disease
stage (Prestia et al., 2013). For this reason, a SG effect depen-
dent on single or multiple biomarker positivity could be hypoth-
esized and taken into account for defining optimal SG protocols.
Patients with MCI could also be stratify into two groups based
on positivity or negativity of biomarkers, in order to investigate
whether cognitively impaired subjects devoid of AD pathology
might have a greater benefit due to less severe neuronal injury
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and, consequently, greater brain reserve (Stern, 2009). Finally, it
could be interesting to verify if there is an association between
biomarkers and methodological parameters cited in the previ-
ous subparagraph: for instance, can patients with a single positive
biomarker or negativity of biomarkers take advantage from SGs
played at lower time intensity (e.g., once at week) or alone at
home compared with patients with multiple positive biomarkers
or positivity of biomarkers, respectively?
Some studies in AD and MCI patients have shown that MRI
and FDG-PET biomarkers may be more sensitive to change than
clinical measures, as reported by Caroli et al. (2014) but regu-
latory agencies have not yet recognized biomarkers as surrogate
outcome measures. This cautious approach is due to the require-
ment that, to be recognized as surrogate outcome measures,
biomarker changes should reliably predict detectable clinical
changes (Aisen, 2011). Unfortunately, the results of random-
ized clinical trials with anti-beta amyloid drugs (Abeta vaccine
AN1792 and bapineuzumab) have until now shown no clini-
cal efficacy despite a change in biomarkers. On the other hand,
use of biomarkers would allow studies with fewer participants,
shorter durations, lower costs, and with the possibility to control
for the specificity of disease-modifying effect (Morris and Selkoe,
2011; Food and Drug Administration: Draft Guidance for Indus-
try. Alzheimer’s Disease: Developing Drugs for the Treatment
of Early Stage Disease, 2013). Recent non-pharmacological stud-
ies that have incorporated hippocampal atrophy as biomarker
outcome have found a disease-modifying benefit of aerobic exer-
cise in early AD over 6 months (Honea et al., 2014), suggesting
that similar results could also be found applying physical and
cognitive SGs.
Conclusions
If the presumed beneficial effects of SGs will be demonstrated
by robust studies, the potential societal impact will be huge con-
sidering the very high prevalence of cognitive impairment due
to AD, the popularity of video games played by baby-boomers
now at risk of dementia, the current lack of effective treatments,
and the cost-effectiveness of these enjoyable interventions. More-
over, video games already marketed to older adults for maintain-
ing cognitive health may be seen as a scale up of a prevention
program in a high-risk subgroup of the population (Alzheimer’s
Disease International, 2014). SGs may represent a motivating,
low-barrier, engaging and sustainable method to improve or at
least delay the decline in specific social, sensory-motor, cognitive
and emotional functions of elderly people (Wiemeyer and Kliem,
2012).
References
Abt, C. (1970). Serious Games. New York, NY: Viking Press.
Aisen, P. S. (2011). Clinical trial methodologies for disease-modifying
therapeutic approaches. Neurobiol. Aging. 32, S64–S66. doi:
10.1016/j.neurobiolaging.2011.09.008
Alvarez, J., and Djaouti, D. (2012). Introduction au Serious Game. Paris, FR:
Question Théoriques.
Alzheimer’s Disease International. (2009). World Alzheimer Report 2009: The
Global Prevalence of Dementia. London: Alzheimer’s Disease International.
Alzheimer’s Disease International. (2010). World Alzheimer Report 2010: The
Global Economic Impact of Dementia. London: Alzheimer’s Disease Interna-
tional.
Alzheimer’s Disease International. (2013). Policy Brief: The Global Impact of
Dementia 2013-2050. London: Alzheimer’s Disease International.
Alzheimer’s Disease International. (2014).World Alzheimer Report 2014: Dementia
and Risk Reduction: An Analysis of Protective and Modifiable Factors. London:
Alzheimer’s Disease International.
Anguera, J. A., Boccanfuso, J., Rintoul, J. L., Al-Hashimi, O., Faraji, F., and
Janowich, J. (2013). Video game training enhances cognitive control in older
adults. Nature 501, 97–102. doi: 10.1038/nature12486
Bahar-Fuchs, A., Clare, L., andWoods, B. (2013). Cognitive training and cognitive
rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia.
Cochrane Database Syst. Rev. 6:CD003260. doi: 10.1002/14651858.CD003260
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., and Jones,
E. (2011). Alzheimer’s disease. Lancet 377, 1019–1031. doi: 10.1016/S0140-
6736(10)61349-9
BIU. (2014). Gamer-Statistiken. Available online at: http://www.biu-online.
de/en/facts/market-figures-2013/gamer-statistics/age-distribution.html
Boulay, M., Benveniste, S., Boespug, S., Jouvelot, P., and Rigaud, A. S. (2011). A
pilot usability study of MINWii, a music therapy game for demented patients.
Technol. Health Care 19, 233–246. doi: 10.3233/THC-2011-0628
Caroli, A., Prestia, A., Wade, S., Chen, K., Ayutyanont, N., and Landau, S. M.
(2014). Alzheimer disease biomarkers as outcome measures for clinical trials
in MCI. Alzheimer Dis. Assoc. Disord. doi: 10.1097/WAD.0000000000000071.
[Epub ahead of print].
De Gloria, A., Bellotti, F., Berta, R., and Lavagnino, E. (2014). Serious Games for
education and training. Int. J. Serious Game 1, 1.
Delrieu, J., Ousset, P. J., Voisin, T., and Vellas, B. (2014). Amyloid beta pep-
tide immunotherapy in Alzheimer disease. Rev. Neurol. 170, 739–748. doi:
10.1016/j.neurol.2014.10.003
Djaouti, D., Alvarez, J., and Jessel, J. P. (2011). “Classifying serious games: the
G/P/S model,” in Handbook of Research on Improving Learning and Motiva-
tion through Educational Games: Multidisciplinary Approaches, ed P. Felicia
(Hershey, PA: IGI Global), 118–136.
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., and
Joffe, S. (2014). Phase 3 trials of solanezumab for mild-to-moderate
Alzheimer’s disease. N. Engl. J. Med. 370, 311–321. doi: 10.1056/NEJMoa
1312889
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., and
Blennow, K. (2014). Advancing research diagnostic criteria for Alzheimer’s
disease: the IWG-2 criteria. Lancet Neurol. 13, 614–629. doi: 10.1016/S1474-
4422(14)70090-0
ESA. (2011). Essential Facts About the Computer and Video Games Indus-
try. Available online at: http://www.isfe.eu/sites/isfe.eu/files/attachments/
esa_ef_2011.pdf
ESA. (2014). Essential Facts About the Computer and Video Games Indus-
try. Available online at: http://www.isfe.eu/sites/isfe.eu/files/attachments/
esa_ef_2014.pdf
Férnandez-Calvo, B., Rodriguez-Pérez, R., Contador, I., Rubio-Santorum, A., and
Ramos, F. (2011). Efficacy of cognitive training programs based on new soft-
ware technologies in patients with Alzheimer-type dementia. Psicothema 23,
44–50.
Food and Drug Administration: Draft Guidance for Industry. Alzheimer’s
Disease: Developing Drugs for the Treatment of Early Stage Dis-
ease. (2013). Available online at: http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.
pdf. (Accessed: February 24, 2013).
Foster, N. L., Hackett, J. S., White, G., Chenevert, S., Svarvar, P., and Bain,
L. (2014). Justifying reimbursement for Alzheimer’s diagnostics and treat-
ments: seeking alignment on evidence. Alzheimers Dement. 10, 503–508. doi:
10.1016/j.jalz.2014.05.003
Frontiers in Aging Neuroscience | www.frontiersin.org 5 March 2015 | Volume 7 | Article 26
Muscio et al. SGs trial design in MCI
Honea, R., Vidoni, E. D., Morris, J., Graves, R., Perea, R. D., and Van
Sciver, A. (2014). Aerobic exercise reduces hippocampal atrophy in
individuals with early Alzheimer’s disease. Alzheimer’s Dement. 10, P303. doi:
10.1016/j.jalz.2014.04.509
Jack, C. R. Jr., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S.,
and Weiner, M. W. (2010). Hypothetical model of dynamic biomarkers
of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119–128. doi:
10.1016/S1474-4422(09)70299-6
Manning, J. (2004). The Emblem. London, UK: Reaktion Books.
Michael, D., and Chen, S. (2005). Serious Games: Games that Educate, Train and
Inform. Boston, MA: Thomson Course Technology PTR Development.
Morris, J. C., and Selkoe, D. J., (2011). Recommendations for the incorporation
of biomarkers into Alzheimer clinical trials: an overview. Neurobiol Aging. 1,
S1–S3. doi: 10.1016/j.neurobiolaging.2011.09.005
Mosimann, U., Tarnanas, I., Dimitriadis, S., Laskaris, N., Bamidis, P.,
and Tsolaki, M. (2014). Serious gaming enhances cognitive function in
MCI due to Alzheimer’s disease. Alzheimer’s Dementia 10, P922. doi:
10.1016/j.jalz.2014.07.135
Nouchi, R., Taki, Y., Takeuchi, H., Hashizume, H., Akitsuki, Y., and Shigemune,
Y. (2012). Brain training game improves executive functions and processing
speed in the elderly: a randomized controlled trial. PLoS ONE 7:e29676. doi:
10.1371/journal.pone.0029676
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B.,
and Barkhof, F. (2013). Prediction of dementia in MCI patients based on
core diagnostic markers for Alzheimer disease. Neurology 80, 1048–1056. doi:
10.1212/WNL.0b013e3182872830
Robert, P. H., König, A., Amieva, H., Andrieu, S., Bremond, F., and Bullock,
R. (2014). Recommendations for the use of Serious Games in people with
Alzheimer’s Disease, related disorders and frailty. Front. Aging Neurosci. 6:54.
doi: 10.3389/fnagi.2014.00054
Rosen, A. C., Sugiura, L., Kramer, J. H., Whiteld-Gabrieli, S., and Gabrieli, J. D.
(2011). Cognitive training changes hippocampal function in mild cognitive
impairment: a pilot study. J. Alzheimers Dis. 26, 349–357. doi: 10.3233/JAD-
2011-0009
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., and Raskind,
M. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate
Alzheimer’s disease. N. Engl. J. Med. 23, 322–333. doi: 10.1056/NEJMoa
1304839
Stavros, Z., Fotini, K., and Magda, T. (2010). “Computer based cognitive train-
ing for patients with mild cognitive impairment (mci),” in Proceedings of the
3rd International Conference on Pervasive Technologies Related to Assistive
Environments, PETRA ′10 (Petras, RI: ACM), 1–3.
Stern, Y. (2009). Cognitive reserve. Neuropsychologia 47, 2015–2028. doi:
10.1016/j.neuropsychologia.2009.03.004
Tarnanas, I., Tsolaki, M., Nef, T., M., Müri, R., and Mosimann, U. P. (2014). Can
a novel computerized cognitive screening test provide additional information
for early detection of Alzheimer’s disease?Alzheimers Dement. 10, 790–798. doi:
10.1016/j.jalz.2014.01.002
Tomaszewski Farias, S., Cahn-Weiner, D. A., Harvey, D. J., Reed, B. R., Mungas,
D., and Kramer, J. H. (2009). Longitudinal changes in memory and exec-
utive functioning are associated with longitudinal change in instrumental
activities of daily living in older adults. Clin. Neuropsychol. 23, 446–461. doi:
10.1080/13854040802360558
Wan Shamsuddin, S. N., Valerie, L., and Hassan, U. (2011). Virtual environment
design guidelines for elderly people in early detection of dementia.World Acad.
Sci. Eng. Technol. 5, 1860–1864.
Weybright, E., Dattilo, J., and Rusch, F. (2010). Effects of an interactive video
game (Nintendo Wii) on older women with mild cognitive impairment. Ther.
Recreation J. 44, 271–287.
Wiemeyer, J., and Kliem, A. (2012). Serious games in prevention and rehabilita-
tion – a new panacea for elderly people? Eur. Rev. Aging Phys. Activ. 9, 41–50.
doi: 10.1007/s11556-011-0093-x
Woods, B., Aguirre, E., Spector, A. E., and Orrell, M. (2012). Cogni-
tive stimulation to improve cognitive functioning in people with demen-
tia. Cochrane Database Syst. Rev. 2:CD005562. doi: 10.1002/14651858.
CD005562
Yamaguchi, H., Maki, Y., and Takahashi, K. (2011). Rehabilitation for demen-
tia using enjoyable video-sports games. Int. Psychogeriatr. 23, 674–676. doi:
10.1017/S1041610210001912
Zinke, K., Zeintl, M., Rose, N. S., Putzmann, J., Pydde, A., and Kliegel, M.
(2014). Working memory training and transfer in older adults: effects of
age, baseline performance, and training gains. Dev. Psychol. 50, 304–315. doi:
10.1037/a0032982
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Muscio, Tiraboschi, Guerra, Defanti and Frisoni. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 6 March 2015 | Volume 7 | Article 26
